- Home
- Publications
- Publication Search
- Publication Details
Title
Afatinib in the treatment of head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 1, Pages 135-143
Publisher
Informa Healthcare
Online
2013-11-25
DOI
10.1517/13543784.2014.858696
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
- (2013) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
- (2013) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
- (2013) Renato G. Martins et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)
- (2013) Vera Hirsh et al. Journal of Thoracic Oncology
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
- (2012) A. R. Abdul Razak et al. ANNALS OF ONCOLOGY
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2012) J. A. de Souza et al. CLINICAL CANCER RESEARCH
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers
- (2011) E.-H. Tan et al. ANNALS OF ONCOLOGY
- Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
- (2011) Peter Stopfer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2011) Vincent Gregoire et al. RADIOTHERAPY AND ONCOLOGY
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
- (2009) J. Simon W. Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
- (2009) Todd D Prickett et al. NATURE GENETICS
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search